Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: UNIPROT:P42345 (
mTOR
)
26,049
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
Tumor suppressor genes evolved as negative effectors of mitogen and nutrient signaling pathways, such that mutations in these genes can lead to pathological states of growth. Tuberous sclerosis (TSC) is a potentially devastating disease associated with mutations in two tumor suppressor genes, TSC1 and 2, that function as a complex to suppress signaling in the
mTOR
/S6K/4E-BP pathway. However, the inhibitory target of TSC1/2 and the mechanism by which it acts are unknown. Here we provide evidence that TSC1/2 is a GAP for the small GTPase
Rheb
and that insulin-mediated
Rheb
activation is PI3K dependent. Moreover,
Rheb
overexpression induces S6K1 phosphorylation and inhibits PKB phosphorylation, as do loss-of-function mutations in TSC1/2, but contrary to earlier reports
Rheb
has no effect on MAPK phosphorylation. Finally, coexpression of a human TSC2 cDNA harboring a disease-associated point mutation in the GAP domain, failed to stimulate
Rheb
GTPase activity or block
Rheb
activation of S6K1.
...
PMID:Insulin activation of Rheb, a mediator of mTOR/S6K/4E-BP signaling, is inhibited by TSC1 and 2. 1282 Sep 60
Recently the tuberous sclerosis complex 2 (TSC2) tumor suppressor gene product has been identified as a negative regulator of protein synthesis upstream of the
mTOR
and ribosomal S6 kinases. Because of the homology of TSC2 with GTPase-activating proteins for Rap1, we examined whether a Ras/Rap-related GTPase might be involved in this process. TSC2 was found to bind to
Rheb
-GTP in vitro and to reduce
Rheb
GTP levels in vivo. Over-expression of
Rheb
but not Rap1 promoted the activation of S6 kinase in a rapamycin-dependent manner, suggesting that
Rheb
acts upstream of
mTOR
. The ability of
Rheb
to induce S6 phosphorylation was also inhibited by a farnesyl transferase inhibitor, suggesting that
Rheb
may be responsible for the Ras-independent anti-neoplastic properties of this drug.
...
PMID:Rheb binds tuberous sclerosis complex 2 (TSC2) and promotes S6 kinase activation in a rapamycin- and farnesylation-dependent manner. 1284 88
Rheb
GTPases represent a unique family of the Ras superfamily of G-proteins. Studies on
Rheb
in Schizosaccharomyces pombe and Drosophila have shown that this small GTPase is essential and is involved in cell growth and cell cycle progression. The Drosophila studies also raised the possibility that
Rheb
is involved in the TOR/S6K signaling pathway. In this paper, we first report identification of dominant negative mutants of S. pombe
Rheb
(SpRheb). Screens of a randomly mutagenized SpRheb library yielded a mutant, SpRhebD60V, whose expression in S. pombe results in growth inhibition, G1 arrest, and induction of fnx1+, a gene whose expression is induced by the disruption of
Rheb
. Alteration of the Asp-60 residue to all possible amino acids by site-directed mutagenesis led to the identification of two particularly strong dominant negative mutants, D60I and D60K. Characterization of these dominant negative mutant proteins revealed that D60V and D60I exhibit preferential binding of GDP, while D60K lost the ability to bind both GTP and GDP. A possible use of the dominant negative mutants in the study of mammalian
Rheb
was explored by introducing dominant negative mutations into human
Rheb
. We show that transient expression of the wild type Rheb1 or Rheb2 causes activation of p70S6K, while expression of Rheb1D60K mutant results in inhibition of basal level activity of p70S6K. In addition, Rheb1D60K and Rheb1D60V mutants blocked nutrient- or serum-induced activation of p70S6K. This provides critical evidence that
Rheb
plays a role in the
mTOR
/S6K pathway in mammalian cells.
...
PMID:Identification of dominant negative mutants of Rheb GTPase and their use to implicate the involvement of human Rheb in the activation of p70S6K. 1286 48
Tuberous sclerosis complex (TSC) is a genetic disease caused by mutation in either TSC1 or TSC2. The TSC1 and TSC2 gene products form a functional complex and inhibit phosphorylation of S6K and 4EBP1. These functions of TSC1/TSC2 are likely mediated by
mTOR
. Here we report that TSC2 is a GTPase-activating protein (GAP) toward
Rheb
, a Ras family GTPase.
Rheb
stimulates phosphorylation of S6K and 4EBP1. This function of
Rheb
is blocked by rapamycin and dominant-negative
mTOR
.
Rheb
stimulates the phosphorylation of
mTOR
and plays an essential role in regulation of S6K and 4EBP1 in response to nutrients and cellular energy status. Our data demonstrate that
Rheb
acts downstream of TSC1/TSC2 and upstream of
mTOR
to regulate cell growth.
...
PMID:Rheb GTPase is a direct target of TSC2 GAP activity and regulates mTOR signaling. 1286 86
Tuberous sclerosis is an autosomal dominant human genetic disorder in which distinctive tumors called hamartomas develop. Germline mutations in either TSC1 or TSC2 cause this syndrome, and hamartomas typically display second hit events with loss of the remaining normal allele. Studies initiated in Drosophila have identified a role for the Tsc1 and Tsc2 genes in the regulation of cell and organ size, and genetic interaction studies have placed them in the PI3K-Akt-
mTOR
-S6K pathway. Biochemical studies have shown that activated Akt phosphorylates TSC2 in the TSC1/TSC2 protein complex, inactivating it; while TSC1/TSC2 has GAP activity for the
Rheb
GTPase (a member of the ras family), and activated
Rheb
-GTP activates
mTOR
. Thus, in cells lacking TSC1 or TSC2 there are increased levels of
Rheb
-GTP which leads to activation of
mTOR
, leading to cell size increase and growth. These developments provide enhanced understanding of this signaling pathway and fundamental insights into the pathogenesis of tuberous sclerosis, and open the possibility of treatment for hamartomas by several pharmacologic approaches.
...
PMID:Rhebbing up mTOR: new insights on TSC1 and TSC2, and the pathogenesis of tuberous sclerosis. 1461 11
The
mammalian target of rapamycin
,
mTOR
, is a protein Ser-Thr kinase that functions as a central element in a signaling pathway involved in the control of cell growth and proliferation. The activity of
mTOR
is controlled not only by amino acids, but also by hormones and growth factors that activate the protein kinase Akt. The signaling pathway downstream of Akt leading to
mTOR
involves the protein products of the genes mutated in tuberous sclerosis, TSC1 and TSC2, and the small guanosine triphosphatase,
Rheb
. In cells,
mTOR
is found in a complex with two other proteins, raptor and mLST8. In this review, we describe recent progress in understanding the control of the
mTOR
signaling pathway and the role of
mTOR
-interacting proteins.
...
PMID:TOR signaling. 1466 32
The
mammalian target of rapamycin
(
mTOR
) controls cell growth in response to amino acids and growth factors, in part by regulating p70 S6 kinase alpha (p70 alpha) and eukaryotic initiation factor 4E binding protein 1 (4EBP1). Raptor (regulatory associated protein of mTOR) is a 150 kDa
mTOR
binding protein that is essential for TOR signaling in vivo and also binds 4EBP1 and p70alpha through their respective TOS (TOR signaling) motifs, a short conserved segment previously shown to be required for amino acid- and
mTOR
-dependent regulation of these substrates in vivo. Raptor appears to serve as an
mTOR
scaffold protein, the binding of which to the TOS motif of
mTOR
substrates is necessary for effective
mTOR
-catalyzed phosphorylation. Further understanding of regulation of the
mTOR
-raptor complex in response to the nutritional environment would require identification of the interplay between the
mTOR
-raptor complex and its upstream effectors such as the protein products of tumor suppressor gene tuberous sclerosis complexes 1 and 2, and the Ras-related small G protein
Rheb
.
...
PMID:Raptor, a binding partner of target of rapamycin. 1468 81
The tumor-suppressor proteins TSC1 and TSC2 are associated with an autosomal dominant disorder known as tuberous sclerosis complex (TSC). TSC1 and TSC2 function as a heterodimer to inhibit cell growth and proliferation. Another protein,
mTOR
(
mammalian target of rapamycin
), is regarded as a central controller of cell growth in response to growth factors, cellular energy and nutrient levels. Recent breakthroughs in TSC research link the TSC1/2 heterodimer protein to the
mTOR
signaling network. It has recently been shown that TSC2 has GTPase-activating protein (GAP) activity towards the Ras family small GTPase
Rheb
(Ras homolog enriched in brain), and TSC1/2 antagonizes the
mTOR
signaling pathway via stimulation of GTP hydrolysis of
Rheb
. Thus, TSC1/2 and
Rheb
have pivotal roles in mediating growth factors, nutrient and energy sensing signals to
mTOR
-dependent targets. These discoveries lend new insight into TSC pathogenesis.
...
PMID:TSC2: filling the GAP in the mTOR signaling pathway. 1472 30
We sought to elucidate the role of AKT in follicle-stimulating hormone (FSH)-mediated granulosa cell (GC) differentiation. Our results define a signaling pathway in GCs whereby the inactivating phosphorylation of tuberin downstream of phosphatidylinositol (PI) 3-kinase/AKT activity leads to
Rheb
(Ras homolog enriched in brain) and subsequent
mTOR
(
mammalian target of rapamycin
) activation.
mTOR
then stimulates translation by phosphorylating p70 S6 kinase and, consequently, the 40 S ribosomal protein S6. Activation of this pathway is required for FSH-mediated induction of several follicular differentiation markers, including luteinizing-hormone receptor (LHR), inhibin-alpha, microtubule-associated protein 2D, and the PKA type IIbeta regulatory subunit. FSH also promotes activation of the transcription factor hypoxia-inducible factor-1 (HIF-1). FSH-stimulated HIF-1 activity is inhibited by the PI 3-kinase inhibitor LY294002, the
Rheb
inhibitor FTI-277 (farnesyltransferase inhibitor-277), and the
mTOR
inhibitor rapamycin. Finally, we find that the FSH-mediated up-regulation of reporter activities for LHR, inhibin-alpha, and vascular endothelial growth factor is dependent upon HIF-1 activity, because a dominant negative form of HIF-1alpha interferes with the up-regulation of these genes. These results show that FSH enhances HIF-1 activity downstream of the PI 3-kinase/AKT/
Rheb
/
mTOR
pathway in GCs and that HIF-1 activity is necessary for FSH to induce multiple follicular differentiation markers.
...
PMID:Follicle-stimulating hormone activation of hypoxia-inducible factor-1 by the phosphatidylinositol 3-kinase/AKT/Ras homolog enriched in brain (Rheb)/mammalian target of rapamycin (mTOR) pathway is necessary for induction of select protein markers of follicular differentiation. 1498 27
The tuberous sclerosis gene products Tsc1 and Tsc2 behave as tumor suppressors by restricting cell growth, a function conserved among metazoans. Recent evidence has indicated that hyperactivation of S6 kinase 1 (S6K1) may represent an important biochemical change in the development of tuberous sclerosis-associated lesions. We show here that deletion of either Tsc1 or Tsc2 or expression of the
Rheb
(Ras homolog enriched in brain) GTPase leads to hyperphosphorylation of S6K1 at a subset of regulatory sites, particularly those of two essential residues functionally conserved among AGC superfamily serine/threonine kinases, i.e. the activation loop (T-loop; Thr-229) and the hydrophobic motif (H-motif; Thr-389). These sites are reciprocally and dose-dependently regulated when S6K1 is coexpressed with the Tsc1-Tsc2 complex. Mutations that render S6K1
mTOR
(
mammalian target of rapamycin
)-resistant also protect S6K1 activity and phosphorylation from down-regulation by Tsc1/2. We demonstrate that two disease-associated mutations in Tsc2 fail to negatively regulate S6K1 activity concomitant with a failure to modify T-loop and H-motif phosphorylation. Finally, we identify one pathological Tsc2 mutation that retains its ability to negatively regulate S6K1, suggesting that, in some cases, tuberous sclerosis may develop independently of S6K1 hyperactivation. These results also highlight the importance of dual control of T-loop and H-motif phosphorylation of S6K1 by the Tsc1-Tsc2 complex.
...
PMID:Critical role of T-loop and H-motif phosphorylation in the regulation of S6 kinase 1 by the tuberous sclerosis complex. 1499 19
1
2
3
4
5
6
7
8
9
10
Next >>